🕒 Last update: loading…

Stock Plus Therapeutics, Inc. PSTV

Plus Therapeutics, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -83.45%

Price change 2019 → 2020: -15.83%

Price change 2020 → 2021: -48.02%

Price change 2021 → 2022: -69.52%

Price change 2022 → 2023: -63.54%

Price change 2023 → 2024: -34.29%

Price change 2024 → 2025: -55.45%

Price change 2025 → 2026: 655.42%

Price change 2026 (year to date): 597.30%

Financial growth

Revenue CAGR (8 years): 8.30%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.21

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -1.24

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 49.21% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Dividends and earnings

Plus Therapeutics, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
15/05/2026-1.05-0.95n/a
12/03/2026-0.83-0.80n/a
30/10/2025-1.00-0.50n/a
14/08/2025-0.25-2.25n/a
30/05/2025-14.00-4.25n/a
27/03/2025-16.75-12.42n/a

Stock splits

DateOperation
02/04/2026reverse split: 1 share for 25
01/05/2023reverse split: 1 share for 15
06/08/2019reverse split: 1 share for 50
24/05/2018reverse split: 1 share for 10
12/05/2016reverse split: 1 share for 15

Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 11/07/2001
ISIN code
US72941H5090
Workforce
21
full-time employees
Chief executive
Marc H. Hedrick

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Plus Therapeutics, Inc.

Is Plus Therapeutics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US72941H5090).

How many employees does Plus Therapeutics, Inc. have?

21 full-time employees according to the latest published profile.

Who runs Plus Therapeutics, Inc.?

Marc H. Hedrick is the company's chief executive.